Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | Immuno-oncology paving the way in MDS

Uma Borate • 1 Jun 2020
EHA 2020
Myelodysplastic Syndromes Antibodies APR-246 Checkpoint inhibitors Durvalumab Magrolimab MBG453 Venetoclax

Uma Borate, MD, Oregon Health & Science University, Portland, OR, outlines novel treatments against myelodysplastic syndromes (MDS). Specifically discussed is the use of antibody-based therapies such as MBG453, small molecule inhibitors such as venetoclax, and therapies including APR246 that targets mutant p53. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Uma Borate

CHIP & CCUS: knowledge gaps, ongoing trials & recommendations for hematologists
Eric Padron et al. • 25 Mar 2024
1:21
Ruxolitinib plus venetoclax in heavily pretreated patients with R/R AML
Uma Borate • 8 Dec 2023
1:34
Impact of pre-treatment features & choice of therapy on outcomes of older adults with AML
Uma Borate • 8 Dec 2023
1:10
Canakinumab in preventing progression of high-risk CCUS to myeloid neoplasms: a Phase II study
Uma Borate • 8 Dec 2023

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
3:19
Key clinical trials in MDS taking place in the US
Guillermo Garcia-Manero • 9 Apr 2024
1:34
Sequencing of agents in LR-MDS
Guillermo Garcia-Manero • 9 Apr 2024
1:21
HMAs for MDS- a party of one
Guillermo Garcia-Manero • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals